【摘要】 目的探讨紫杉醇联合蒽环类药物±CTX方案与CAF方案治疗晚期乳腺癌的近期临床疗效和不良反应。方法以紫杉醇联合蒽环类药物±CTX方案为观察组,CAF方案为对照组。结果观察组有效率为72.7%(16/22),对照组为53.8%(14/26),观察组优于对照组,但无显著性差异(P>0.05)。年龄,月经状况,ER、PR,基因表达,临床分期,远处转移等因素,对近期疗效无显著影响(P>0.05)。不良反应以白细胞减少为主,观察组Ⅲ-Ⅳ度发生率为59.1%,对照组为11.5%,两组比较有显著性差异(P<0.01),其他与化疗相关的不良反应程度均较轻,可耐受。结论对于晚期乳腺癌初用化疗者,CAF组与观察组相比疗效无显著差异且不良反应较轻,临床更具优势,值得临床广泛应用。更多还原

【Abstract】 Objective To study the short-term efficacy and toxicities of combined paclitaxel plus antracycline ±CTX and CAF treatment for advanced breast cancer.Methods Patients treated with paclitaxel plus antracycline ±CTX were included in the study group,and patients treated with the CAF were included in the control group.Results The response rate was 72.7%(16/22) for the study group,and 53.8%(14/26) for the control group,with no significant differences(P>0.05).Age,menstruation status,ER,PR,gene expression,clinical TNM stage and distant metastases had no significant correlations with the short-term clinical efficacy(P>0.05).The major toxicity was leucopenia,with 59.1% and 11.5% patients having Ⅲ-Ⅳ leucopenia in the study and control group,respectively.This difference was statistically significant(P<0.01).Other chemotherapy-related toxicities were mild and tolerable.Conclusion CAF chemotherapy has the same efficacy as the paclitaxel plus antracycline ±CTX regime,but with less toxicities,in the treatment of patients with advanced breast cancer.更多还原